Search the Newsreel

Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Bioscience Corp. has signed a Material Transfer Agreement (MTA) with PegBio Co., Ltd to evaluate Lexaria's DehydraTECH technology with PegBio's proprietary GLP-1 molecule for the GLP-1 industry. This collaboration aims to enhance the accessibility and effectiveness of PegBio's GLP-1-related drug products, which target …

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …

Avoiding Lag: Real-Time Signals in (TYRA) Movement

The article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near-term and mid-term sentiment despite a long-term positive outlook. It provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Report - Results, Call & Slides

Alamar Biosciences, Inc. (ALMR) reported its Q2 2026 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of -$0.22 against a consensus of -$0.31, and actual revenue of $29.40 million compared to an expected $25.86 million. The earnings call took …

News by ACCESS Newswire on TradingView, 2026-08-13

Lexaria Bioscience Corp. has announced a Material Transfer Agreement (MTA) with PegBio Co., Ltd to explore Lexaria's DehydraTECH technology with a proprietary PegBio GLP-1 molecule for the GLP-1 industry. This collaboration aims to evaluate the pharmacokinetic performance of the combined technology in animal studies, …

Microbix Biosystems Q3 2026 Earnings Call Transcript

Earnings Flash (MBX.TO) Microbix Biosystems Inc. Reports Q3 Revenue C$4.1M

HC Wainwright Has Bullish Outlook for DTIL FY2030 Earnings

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Artelo Biosciences Clinical and Scientific Progress Across the Pipeline Supports Multiple Upcoming Milestones SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for …

Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

(RTTNews) - Cellectar Biosciences, Inc. (CLRB) reported second-quarter 2026 results, highlighting increased R&D investment and a stronger balance sheet compared to the prior year. The company advanced its oncology pipeline with progress in pivotal and early-stage trials, while preparing for a Phase 3 confirmatory …

Kuros Biosciences AG legt Ergebniszahlen für das Halbjahr bis zum 30. Juni 2026 vor

Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M

Cellectar Biosciences reported a net loss of $6.9 million for Q2 2026, an increase from $5.4 million in Q2 2025, driven by higher R&D expenses. The company's cash and cash equivalents rose to $34.0 million, up from $13.2 million at the end of 2025, …

Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing

Cellectar Biosciences reported its Q2 2026 financial results, including a $6.9 million net loss, and provided significant corporate updates. The company is advancing its radiotherapeutic pipeline, most notably initiating site activation for a Phase 3 confirmatory trial for iopofosine I 131 in Waldenström macroglobulinemia, …

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its oncology pipeline. Key developments include the initiation of site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström Macroglobulinemia (WM), with an NDA …

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded Emergent BioSolutions (NYSE:EBS) to a "Hold" rating. Despite beating Q2 earnings estimates, the company faces analyst forecasts for a full-year loss, increased competition, and pricing pressure, leading to a significant impairment charge against its NARCAN franchise. The stock currently has a …

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a …

Microbix Biosystems Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

HC Wainwright Analysts Increase Earnings Estimates for JBIO

Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold

Zacks Research has downgraded Harmony Biosciences (NASDAQ:HRMY) from a "strong buy" to a "hold" rating, aligning with the overall consensus. Despite the downgrade, Harmony Biosciences reported a strong quarter with EPS of $1.28 and revenue of $261.28 million, exceeding analyst expectations. The stock opened …

Analysts Offer Insights on NA Companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ) and Amentum Holdings, Inc. (AMTM)

This article summarizes recent analyst ratings for three North American companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ), and Amentum Holdings, Inc. (AMTM). Bank of America Securities reiterated a Hold rating on Alamar Biosciences and a Buy rating on NIQ Global Intelligence, …

Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk

Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary

Cellectar Biosciences reported a consolidated net loss of $(12.6M) and diluted loss per share of $(1.52) for the six months ended June 30, 2026. The company remains pre-revenue but achieved clinical milestones including positive Phase 2 results for CLOVER WaM and FDA Breakthrough Therapy …

Wasatch Advisors LP Sells 175,687 Shares of Castle Biosciences, Inc. $CSTL

Wasatch Advisors LP significantly reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by selling 175,687 shares, representing a 38.6% decrease, and now holds 279,349 shares valued at approximately $6.66 million. Despite this reduction by Wasatch Advisors, institutional investors collectively own 92.6% of CSTL. The …

Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com

Citizens has lowered its price target for Spruce Biosciences (NASDAQ:SPRB) from $150.00 to $144.00, citing potential share dilution, while maintaining a Market Outperform rating. Despite the reduction, the new target still indicates significant upside, although InvestingPro data suggests the stock may be overvalued at …

TuHURA Biosciences (HURA) Earnings Date and Reports 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

Benchmark raises Harvard Bioscience stock price target on revenue beat

Benchmark has increased its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00, maintaining a Speculative Buy rating after the company surpassed second-quarter revenue guidance. The company reported $22.7 million in revenue, exceeding both management's and consensus estimates, and subsequently raised its full-year …

Kuros Biosciences AG bestätigt Ergebnisprognose für die Jahre 2026 und 2028

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences announced its second-quarter 2026 financial results and provided updates on its TA-ERT program for MPS IIIB. The company anticipates submitting a Biologics License Application (BLA) in Q4 2026 and initiating the TrAnsform confirmatory study and an Expanded Access Program (EAP) around the …

Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

Sagimet Biosciences (NASDAQ:SGMT) Director Sells 20,206 Shares of Stock

Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer

Cytek Biosciences (CTKB) has granted new equity awards to its Chief Legal Officer and Secretary, Ilan Feuchtwang. These awards include 241,416 Restricted Stock Units (RSUs) and an option to purchase 127,118 shares of common stock at an exercise price of $4.66 per share. Both …

Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $14,182,880.88 in Stock

Twist Bioscience CEO Emily Leproust sold 113,318 shares of company stock for over $14.18 million, reducing her ownership by 12.16%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan, with the stock trading near its one-year high. Despite missing EPS estimates, analysts …

Twist Bioscience CEO Emily Leproust Executes Stock Option Exercise and Sells 113,318 Shares Under 10b5-1 Plan

Emily M. Leproust, CEO of Twist Bioscience Corp (NASDAQ:TWST), exercised stock options for 113,318 shares and subsequently sold them for a weighted average price of $125.1615 per share on August 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan established in …

Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person

Aura Biosciences, Inc. (AURA) has filed a Form 3, an initial statement of beneficial ownership, for its new Chief People Officer, Julie Person. This filing registers her status as an officer of the company, but it indicates no transactions or current holdings of company …

Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS

Forte Biosciences (NASDAQ:FBRX) announced its quarterly earnings, reporting a loss of $0.97 EPS, which missed analysts' consensus estimate of a $0.88 loss by $0.09. The company's shares are trading near their 52-week high, with significant trading volume, and institutional investors holding a large percentage …